Sarepta Therapeutics Inc Stock Nasdaq
Equities
US0023461041
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | 1.85B | Sales 2025 * | 2.9B | Capitalization | 12.17B |
---|---|---|---|---|---|
Net income 2024 * | 214M | Net income 2025 * | 1B | EV / Sales 2024 * | 5.93 x |
Net cash position 2024 * | 1.2B | Net cash position 2025 * | 2.59B | EV / Sales 2025 * | 3.3 x |
P/E ratio 2024 * |
56.5
x | P/E ratio 2025 * |
12.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.13% |
Latest transcript on Sarepta Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 14-12-31 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
M. Wilsey
CHM | Chairman | 71 | 09-03-30 |
Richard Barry
BRD | Director/Board Member | 65 | 15-06-01 |
1st Jan change | Capi. | |
---|---|---|
-2.25% | 103B | |
+1.52% | 95.28B | |
+3.00% | 22.15B | |
-16.00% | 21.02B | |
-8.38% | 18.15B | |
-41.01% | 16.73B | |
-13.87% | 16.05B | |
+4.01% | 13.68B | |
-23.12% | 8.24B |